Related Experiment Video
Updated: Mar 12, 2026
10:25
Assessment of Lymphocyte Migration in an Ex Vivo Transmigration System
Published on: September 20, 2019
7.4K
Targeting the T Helper 2 Inflammatory Axis in Atopic Dermatitis
Adriana S Moreno1, Roderick McPhee, Luisa Karla Arruda
1Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
International Archives of Allergy and Immunology
|November 16, 2016
Summary
Atopic dermatitis (AD) treatments focus on inflammation and skin barrier repair. New therapies targeting the T helper 2 (Th2) pathway show promise for better atopic dermatitis management.
Area of Science:
- Immunodermatology
- Atopic Dermatitis Pathogenesis
- Inflammatory Skin Diseases
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition affecting children and adults.
- Moderate to severe AD involves skin barrier disruption and T helper 2 (Th2)-driven inflammation.
- Current AD treatments aim to reduce inflammation and restore skin barrier function, but often provide temporary relief and can have side effects.
Purpose of the Study:
- To review current therapeutic strategies for atopic dermatitis (AD).
- To explore the role of the T helper 2 (Th2) immune pathway in AD pathogenesis.
- To discuss emerging antibody therapies and small molecules targeting specific immune pathways in AD.
Main Methods:
- Review of existing literature on atopic dermatitis (AD) treatments.
- Analysis of the role of T helper 2 (Th2) cells and associated cytokines in AD.
- Evaluation of the efficacy and limitations of current and investigational therapies.
Main Results:
- Previous antibody therapies have shown limited success in treating AD.
- Targeting specific immune and molecular pathways offers potential for improved AD management.
- Novel monoclonal antibodies and small molecules are under development for AD.
Conclusions:
- There is a need for more effective and targeted therapies for atopic dermatitis (AD).
- Targeting the Th2 axis presents a promising strategy for future AD treatments.
- Investigational therapies hold potential for more consistent and sustained clinical improvement in AD patients.
Related Concept Videos
01:24T Cell Types and Functions
3.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.0K
01:29Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
111
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
111
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.1K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.1K
01:28Inflammatory Response
17.9K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
17.9K
01:26Asthma-II: Pathophysiology and Classification
4.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.7K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.1K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.1K